Loading...
Market
What will be the market cap rank of Relay Therapeutics among biotech companies by December 31, 2024?
3
Resolution / Starting Odds
Top 10 • 25%
Top 20 • 25%
Top 30 • 25%
Below Top 30 • 25%
Financial market data from reputable sources like Bloomberg or Yahoo Finance
Story
Relay Therapeutics' RLY-2608 Shows Positive Interim Data, Stock Rises 21.2%
Sep 9, 2024, 11:15 AM
Relay Therapeutics announced on Monday positive interim data for its experimental treatment, RLY-2608, which demonstrates clinically meaningful progression-free survival in patients with HR+/HER2- breast cancer. The early-stage study indicates that the combination treatment significantly extended the time patients lived without their disease worsening. Following the announcement, Relay Therapeutics' stock (RLAY) saw a pre-market increase of 21.2%. Dr. Don Bergstrom, President of R&D at Relay Therapeutics, highlighted the significance of these findings.
View original story
Similar markets
Top 50 • 25%
Top 100 • 25%
Top 200 • 25%
Below Top 200 • 25%
Top 5 • 25%
Top 10 • 25%
Top 20 • 25%
Below Top 20 • 25%
Top 10 • 25%
Top 20 • 25%
Top 30 • 25%
Outside Top 30 • 25%
Below $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
Above $3 billion • 25%
Top 10 • 25%
Top 20 • 25%
Top 50 • 25%
Below Top 50 • 25%
Less than $1 billion • 25%
$1 billion to $5 billion • 25%
$5 billion to $10 billion • 25%
More than $10 billion • 25%
Top 10 • 25%
Top 20 • 25%
Top 50 • 25%
Outside Top 50 • 25%
Top 5 • 33%
Top 10 • 33%
Below top 10 • 33%
Top 10 • 25%
Top 20 • 25%
Top 50 • 25%
Below Top 50 • 25%
Below $2 billion • 25%
$2 billion to $4 billion • 25%
$4 billion to $6 billion • 25%
Above $6 billion • 25%
1st • 25%
2nd • 25%
3rd • 25%
4th or lower • 25%